CompagOs develops Bon3OID™ in vitro bone models using 3D bioprinting technology to create biologically relevant human bone tissue for research and drug testing. The company addresses the need for effective therapies in bone health, particularly for rare bone diseases and bone oncology, by providing a platform for drug efficacy and toxicity assessments.
Funding
$117.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for studying bone diseases and testing potential treatments often rely on animal models or traditional 2D cell cultures, which fail to accurately replicate the complex 3D microenvironment of human bone tissue. This leads to difficulties in predicting drug efficacy and potential toxicity in humans, hindering the development of effective therapies for bone-related conditions.
Solution
CompagOs develops Bon3OID™, 3D bioprinted in vitro bone models using human cells to create biologically relevant bone tissue for research and drug development. These organotypic bone models mimic the complex architecture and cellular environment of native bone, providing a robust platform for researchers to study bone physiology, disease mechanisms, and drug responses. By incorporating patient-derived cells and applying biomechanical stimulation, CompagOs creates personalized bone models that enable more accurate and reliable preclinical testing of drug candidates and personalized medicine approaches. The models can be customized to include various bone cell types, such as osteoblasts, osteocytes, osteoclasts, and cancer cells, to address specific research and clinical needs.
Target Audience
CompagOs' primary customers are researchers in academia and the pharmaceutical industry, as well as clinicians seeking advanced tools for drug development, personalized medicine, and regenerative treatments in bone health.
Features
- 3D bioprinting of human mesenchymal stem cell-laden hydrogel scaffolds from healthy or diseased donors
- Cyclic mechanical loading to stimulate cell-mediated mineralization, mimicking the mechanical load exerted on bones during everyday activities
- Customizable cell composition, including osteoblasts, osteocytes, osteoclasts, and cancer cells
- Multiscale assessment capabilities to study mineral formation, scaffold stiffness, and cell morphology
- Compatibility with various analytical techniques, including imaging, biochemical assays, and molecular analyses
- Option to use patient-specific cells for personalized disease modeling and drug testing